WWP
AMRX icon

WR Wealth Planners’s Amneal Pharmaceuticals AMRX Stock Holding History

WR Wealth Planners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59
Closed -$375 – 1144
2024
Q2 		$375 Hold
59
– – ﹤0.01% 1049
2024
Q1 		$358 Buy
+59
New +$333 ﹤0.01% 1074

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WR Wealth Planners's AMRX Position: Q3 2024 in Review

WR Wealth Planners sold out of Amneal Pharmaceuticals (AMRX) in Q3 2024, closing a stake of 59 shares — an estimated $375 sold.

WR Wealth Planners first reported a position in AMRX in Q1 2024 and held it in 2 quarters. The position peaked at $375 in Q2 2024. 183 funds tracked by Wall St. Rank hold AMRX as of Q3 2024.

  • WR Wealth Planners reported no remaining Amneal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • WR Wealth Planners sold 59 Amneal Pharmaceuticals shares in Q3 2024, an estimated $375.
  • WR Wealth Planners first reported a position in Amneal Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • WR Wealth Planners's Amneal Pharmaceuticals position peaked at $375 in Q2 2024.
  • 183 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2024.

Based on WR Wealth Planners's 13F filing for Q3 2024, filed 17 Oct 2024.